Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2009. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity plan transactions.
- Share Price: Ordinary shares at £10.39 per share.
- ADR Price: Ordinary Share ADRs at $30.85 per ADR.
- Transaction Type: Increase in notional interests following the notional re-investment of the dividend to be paid on July 9, 2009.
Material Changes
The filing details an increase in notional share interests for 16 named individuals, including Mr. A.P. Witty and Mr. J.S. Heslop. These changes result from the automatic re-investment of dividends within the Performance Share Plan rather than open market purchases or sales.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three-year measurement period. No specific risks or contingencies are disclosed in this document.
Investor Verification Checklist
- Verify the vesting schedule and performance conditions for the GlaxoSmithKline Performance Share Plan to understand the actual economic value of the notional increases.
- Confirm the dividend payment date of July 9, 2009, and the dividend per share amount used for the re-investment calculation.
- Review the full list of participants to assess the concentration of notional holdings among senior management.